Lantern Pharma: AI-Based Drug Discovery and Development Targeting Cancer

Facebooktwitterlinkedinmail

Lantern Pharma (NASDAQ: LTRN) is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to transform the cost, risk and timeline of oncology drug discovery and development. Lantern utilizes its proprietary RADR® A.I. platform to discover and develop precision oncology therapeutics using defined genetic biomarkers to identify patients who are most likely to respond to the therapy. Lantern has three drug candidates in four active development programs. Two programs are in phase 2. And, two programs are in pre-clinical stage. The Phase 2 programs are in Non-Small Cell Lung Cancer (“NSCLC”) among never smokers and in metastatic hormone resistant Prostate Cancer (mCRPC). The two preclinical programs are in various solid tumors and Glioblastoma, a particularly deadly form of brain cancer. Prognosis in each disease area being pursued with Lantern’s A.I. derived compounds remains poor. All currently used therapies eventually fail. Creating high unmet medical need. And, significant opportunities to make a real difference in the lives of patients who are left with very few, if any, options

Facebooktwitterlinkedinmail